Why the study?
Pharmacological cardioversion of AF is frequently inefficacious, prompting the first-in-human evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of AP30663, a novel KCa2 channel inhibitor.
Is intravenous AP30663 safe and well-tolerated in healthy male volunteers?
Is intravenous AP30663 safe and well-tolerated in healthy male volunteers?
In a first-in-human study, the novel KCa2 channel inhibitor AP30663 was systemically safe and well-tolerated, supporting its further development for pharmacological cardioversion of atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
QTc prolongation and infusion reactions warrant caution in dosing; extends first-in-human safety data for KCa2 inhibition in AF.
Gal et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: